References
- Wimo A, Prince M. World Alzheimer Report 2010. Alzheimer’s Disease International, London, UK (2010).
- Department of Health. Living Well with Dementia: a National Dementia Strategy. Department of Health, London, UK (2009).
- Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet377(9770), 1019–1031 (2011).
- Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst. Rev.1, CD001747 (2006).
- Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst. Rev.2, CD001191 (2009).
- Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev.1, CD001190 (2006).
- NICE National Institute for Health and Clinical Excellence. Final Appraisal Determination. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of NICE technology appraisal guidance 111). NICE, London, UK (2011).
- Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol.6(8), 734–746 (2007).
- Jorm AF. Methods of screening for dementia: a meta-analysis of studies comparing an informant questionnaire with a brief cognitive test. Alzheimer’s Dis. Assoc. Disord.11(3), 158–162 (1997).
- Mackinnon A, Mulligan R. Combining cognitive testing and informant report to increase accuracy in screening for dementia. Am. J. Psych.155(11), 1529–1535 (1998).
- Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst. Rev.4, CD001877 (2011).
- Ilic D, O’Connor D, Green S, Wilt TJ. Screening for prostate cancer. Cochrane Database Syst. Rev.3, CD004720 (2006).
Websites
- Dementia UK report, Alzheimer’s Society (2007) www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=342
- Alzheimer’s Society (2011) www.alzheimers.org.uk/dementiamap